Page last updated: 2024-11-07

u 54494a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 54494A: RN given refers to (trans)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID183469
SCHEMBL ID10340144
MeSH IDM0153205

Synonyms (15)

Synonym
u 54494a
cis-3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)benzamide monohydrochloride
unii-2bz8zbr9lf
112465-94-8
benzamide, 3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-, monohydrochloride, cis-
2bz8zbr9lf ,
u-54494a hydrochloride
SCHEMBL10340144
sr-01000597738
SR-01000597738-1
3,4-dichloro-n-methyl-n-[(1r,2s)-2-pyrrolidin-1-ylcyclohexyl]benzamide;hydrochloride
benzamide, 3,4-dichloro-n-methyl-n-((1r,2s)-2-(1-pyrrolidinyl)cyclohexyl)-, hydrochloride (1:1), rel-
3,4-dichloro-n-methyl-n-[2-(pyrrolidin-1-yl)cyclohexyl]benzamide--hydrogen chloride (1/1)
DTXSID90920763
u-54494ahydrochloride

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A comparative pharmacokinetic study with intravenous and oral administration of the two individual enantiomers to the dog was conducted to evaluate the potential enantioselective pharmacokinetics of U-54494."( Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog.
Jones, BW; Schuette, MR; Vandegiessen, TL; Williams, MG; Zhong, WZ, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
" These results suggested that the (+)-enantiomer appeared to be more extensively metabolized by first-pass effect than the (-)-enantiomer after oral dosing, and as a result, oral bioavailability for the (+)-enantiomer is only one half of that for its antipode (12."( Pharmacokinetics of the individual enantiomers of cis-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]-benzamide monohydrochloride (U-54494A) in the dog.
Jones, BW; Schuette, MR; Vandegiessen, TL; Williams, MG; Zhong, WZ, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
"A morphometric study of kainic acid- (KA) induced lesions was designed for the study of the interaction of the diamines U-5449A and U-50488H with excitatory amino acids, and the dose-response relationship thereof."( Antagonism of kainic acid lesions in the mouse hippocampus by U-54494A and U-50488H.
Aaron, CS; Camacho Ochoa, M; Jackson, TA; Lahti, RA; Strain, GM; Von Voigtlander, PF, 1992
)
0.28
" Animals treated with U-50488H on a similar dosing schedule showed significant neuroprotection at all doses tested, with peak protection observed at 30 mg/kg (51."( The kappa opioid-related anticonvulsants U-50488H and U-54494A attenuate N-methyl-D-aspartate induced brain injury in the neonatal rat.
Althaus, JS; Hudson, CJ; Means, ED; Scherch, HM; Von Voigtlander, PF, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (9.52)18.7374
1990's19 (90.48)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]